162652-95-1 Usage
Description
Vinflunine, also known as PM391 and marketed under the brand name Javlor, is a semisynthetic analog of the natural vinca alkaloids vinblastine and vincristine. It is an organic heteropentacyclic compound and an organic heterotetracyclic compound, synthesized from anhydrovinblastine in a superacid media (HF-SbF5) and in the presence of a chlorinated solvent like CHCl3 or CCl4. Vinflunine was approved by the European Medicines Agency (EMEA) in 2009 for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen.
Uses
Used in Oncology:
Vinflunine is used as an anticancer agent for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract. It is particularly effective in cases where patients have failed a prior platinum-containing regimen. Vinflunine works by inhibiting microtubule assembly, which leads to cell cycle arrest and apoptosis in cancer cells.
Used in Pharmaceutical Industry:
Vinflunine is used as an active pharmaceutical ingredient in the development of cancer treatments. Its unique mechanism of action and approval for specific patient populations make it a valuable addition to the oncology drug market. The synthesis process and formulation of Vinflunine can be further optimized and studied to improve its efficacy, safety, and accessibility for patients in need.
Originator
Pierre Fabre (France)
Clinical Use
Antineoplastic agent (vinca alkaloid): Treatment of advanced or metastatic bladder cancer
Drug interactions
Potentially hazardous interactions with other drugs
Antibacterials: possible increased risk of ventricular
arrhythmias with delamanid; concentration possibly
reduced by rifampicin - avoid.
Antidepressants: concentration possibly reduced by
St Johns wort - avoid.
Antifungals: concentration increased by ketoconazole
and possibly itraconazole (increased risk of
neurotoxicity) - avoid.
Antimalarials: avoid with piperaquine with
artenimol.
Antipsychotics: avoid with clozapine (increased risk
of agranulocytosis).
Antivirals: concentration possibly increased by
ritonavir - avoid.
Grapefruit juice: concentration of vinflunine
increased - avoid.
Metabolism
Metabolised by the cytochrome CYP3A4 isoenzyme,
except for 4-O-deacetylvinflunine (DVFL), the only
active metabolite and main metabolite in blood which
is formed by multiple esterases. Excretion occurs via the
faeces (about two-thirds) and the urine (about one-third).
Check Digit Verification of cas no
The CAS Registry Mumber 162652-95-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,2,6,5 and 2 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 162652-95:
(8*1)+(7*6)+(6*2)+(5*6)+(4*5)+(3*2)+(2*9)+(1*5)=141
141 % 10 = 1
So 162652-95-1 is a valid CAS Registry Number.
InChI:InChI=1/C45H54F2N4O8/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44/h9-14,19-20,26-27,36-38,48,55H,8,15-18,21-24H2,1-7H3/t26-,27-,36-,37+,38+,42+,43+,44-,45-/m0/s1